Primary Formulary Step Therapy
August 10, 2023Performance Formulary Changes
August 10, 2023Upcoming Formulary Changes
BeneCard PBF is committed to providing innovative clinical solutions, valuable trend management strategies, and the highest quality of service. We regularly conduct a review of our formulary to remain current with the ever-changing prescription drug landscape.
During this review process, we consider changes that occur with new FDA approvals (brand and generic) and the latest clinical information. This comprehensive review looks at each therapeutic category to identify clinically superior products at the lowest net cost. This process is essential to help control pharmaceutical spend as drug costs, particularly for already costly specialty medications, increase over time. Our goal when considering updates to our formularies is to improve member health outcomes while maximizing plan savings.
October 2023 Changes
The following changes to the Primary Formulary will go into effect on October 1, 2023.
| Moved from Non-Preferred to Preferred | Most Common Indication/Use |
|---|---|
| OVIDREL | Infertility |
| AZSTARYS | ADHD |
| GLATOPA | Multiple Sclerosis |
| Moved from Preferred to Non-Preferred | Most Common Indication/Use |
|---|---|
| DIVIGEL | Menopausal Symptoms |
| NOVAREL | Infertility |
BeneCard PBF appreciates your trust and support in serving your healthcare needs through your pharmacy benefit program. If you have any questions, please contact your BeneCard PBF Account Executive, or call our Client Service Center at 1-877-587-2239.